Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB
Hot flashes are a complication of androgen deprivation therapy for prostate cancer. A phase III study showed that use of low-dose gabapentin was well tolerated and moderately decreased the frequency of hot flashes due to androgen deprivation therapy when taken for 4 weeks. The current study, an open...
Saved in:
Published in | The Journal of supportive oncology Vol. 8; no. 3; p. 128 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.05.2010
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Hot flashes are a complication of androgen deprivation therapy for prostate cancer. A phase III study showed that use of low-dose gabapentin was well tolerated and moderately decreased the frequency of hot flashes due to androgen deprivation therapy when taken for 4 weeks. The current study, an open-label continuation of the randomized study, examined the efficacy and toxicity of gabapentin when taken for (an additional) 8 weeks. Patients were allowed to start, or continue, gabapentin and to titrate the dose to maximum efficacy, up to 900 mg/d. They were asked to complete a hot flash diary daily and keep weekly logs of toxicity, satisfaction with hot flash control, and quality of life. The moderate reduction in hot flash frequency and severity in the randomized phase of the study appeared to be maintained during this continuation phase. Men originally receiving the placebo or lowest dose of gabapentin (300 mg/d) had improved hot flash control relative to that at the end of the randomized phase. Minimal adverse effects were reported. These findings suggest that low-dose gabapentin is moderately efficacious for at least 12 weeks of hot flash treatment in men undergoing androgen deprivation therapy for prostate cancer and seems to be well tolerated. (NCT00028572) |
---|---|
AbstractList | Hot flashes are a complication of androgen deprivation therapy for prostate cancer. A phase III study showed that use of low-dose gabapentin was well tolerated and moderately decreased the frequency of hot flashes due to androgen deprivation therapy when taken for 4 weeks. The current study, an open-label continuation of the randomized study, examined the efficacy and toxicity of gabapentin when taken for (an additional) 8 weeks. Patients were allowed to start, or continue, gabapentin and to titrate the dose to maximum efficacy, up to 900 mg/d. They were asked to complete a hot flash diary daily and keep weekly logs of toxicity, satisfaction with hot flash control, and quality of life. The moderate reduction in hot flash frequency and severity in the randomized phase of the study appeared to be maintained during this continuation phase. Men originally receiving the placebo or lowest dose of gabapentin (300 mg/d) had improved hot flash control relative to that at the end of the randomized phase. Minimal adverse effects were reported. These findings suggest that low-dose gabapentin is moderately efficacious for at least 12 weeks of hot flash treatment in men undergoing androgen deprivation therapy for prostate cancer and seems to be well tolerated. (NCT00028572) |
Author | Szydlo, Daniel W Atherton, Pamela J Barton, Debra L Stella, Philip J Schaefer, Paul L Loprinzi, Charles L Moraska, Amanda R Rowland, Jr, Kendrith M Bearden, James D Krook, James |
Author_xml | – sequence: 1 givenname: Amanda R surname: Moraska fullname: Moraska, Amanda R organization: Mayo Clinic Rochester, Rochester, Minnesota 55905, USA – sequence: 2 givenname: Pamela J surname: Atherton fullname: Atherton, Pamela J – sequence: 3 givenname: Daniel W surname: Szydlo fullname: Szydlo, Daniel W – sequence: 4 givenname: Debra L surname: Barton fullname: Barton, Debra L – sequence: 5 givenname: Philip J surname: Stella fullname: Stella, Philip J – sequence: 6 givenname: Kendrith M surname: Rowland, Jr fullname: Rowland, Jr, Kendrith M – sequence: 7 givenname: Paul L surname: Schaefer fullname: Schaefer, Paul L – sequence: 8 givenname: James surname: Krook fullname: Krook, James – sequence: 9 givenname: James D surname: Bearden fullname: Bearden, James D – sequence: 10 givenname: Charles L surname: Loprinzi fullname: Loprinzi, Charles L |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20552926$$D View this record in MEDLINE/PubMed |
BookMark | eNo1kEFOwzAURL0ooqVwBfQvEMlx4thlBxEUpKosyL76TuzWKLEj26nUDWcnCFiN9Gb0FnNDFs47vSCrnJdlVolNuSQ3MX5SWsi8YNdkySjnbMOqFfnaosJRu2QdGB8gnTQM6PCohxmCN3DyCUyP8aQjzKMx-JgwaWjRtTpAnMLZnn2ID4DQe3e0aeqswx5a_2OdMFnv4GOml2xf180WmmDnek9p_XRLrgz2Ud_95Zo0L89N_Zrt3rdv9eMuG3PGU5Yj3XDe5oIqLGRbdUIKWukWmRS6oLTT5RyqVEgN66SSinFKRW6E7Jgp2Jrc_2rHSQ26O4zBDhguh_8f2DdJmVul |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
ExternalDocumentID | 20552926 |
Genre | Clinical Trial, Phase III Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: CA-35195 – fundername: NCI NIH HHS grantid: CA-60276 – fundername: NCI NIH HHS grantid: CA-35269 – fundername: NCI NIH HHS grantid: CA-124477 – fundername: NCI NIH HHS grantid: U10 CA035269 – fundername: NCI NIH HHS grantid: U10 CA035103 – fundername: NCI NIH HHS grantid: U10 CA052352 – fundername: NCI NIH HHS grantid: CA-37404 – fundername: NCI NIH HHS grantid: K05 CA124477 – fundername: NCI NIH HHS grantid: CA-37417 |
GroupedDBID | --- --K 2WC 4CK 6PF AAWTL AEKER AGYEJ ALMA_UNASSIGNED_HOLDINGS CGR CUY CVF ECM EIF EJD F5P FEDTE FNPLU HVGLF HZ~ J1W M41 N9A NPM P2P RIG ROL SES UDS |
ID | FETCH-LOGICAL-p125t-1a0955c170ba38c6d78706eca287e300de4e30b4ba0f2d8b8b250071f78d2f32 |
ISSN | 1544-6794 |
IngestDate | Sat Sep 28 07:47:44 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p125t-1a0955c170ba38c6d78706eca287e300de4e30b4ba0f2d8b8b250071f78d2f32 |
PMID | 20552926 |
ParticipantIDs | pubmed_primary_20552926 |
PublicationCentury | 2000 |
PublicationDate | 2010 May-Jun |
PublicationDateYYYYMMDD | 2010-05-01 |
PublicationDate_xml | – month: 05 year: 2010 text: 2010 May-Jun |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The Journal of supportive oncology |
PublicationTitleAlternate | J Support Oncol |
PublicationYear | 2010 |
References | 7817208 - Urol Nurs. 1994 Dec;14(4):155-8 8028614 - N Engl J Med. 1994 Aug 11;331(6):347-52 8308973 - J Urol. 1994 Mar;151(3):634-6 9743058 - South Med J. 1998 Sep;91(9):855-7 10379749 - J Urol. 1999 Jul;162(1):98-102 12576259 - Obstet Gynecol. 2003 Feb;101(2):337-45 9381242 - Soc Sci Med. 1997 Oct;45(8):1299-309 1736500 - Urology. 1992 Feb;39(2):108-10 19129205 - Ann Oncol. 2009 Mar;20(3):542-9 2465644 - Urology. 1989 Mar;33(3):175-8 10071307 - J Clin Oncol. 1999 Mar;17(3):1087-8 15473404 - Mayo Clin Proc. 2004 Oct;79(10):1247-51 |
References_xml | |
SSID | ssj0038132 |
Score | 2.0652122 |
Snippet | Hot flashes are a complication of androgen deprivation therapy for prostate cancer. A phase III study showed that use of low-dose gabapentin was well tolerated... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 128 |
SubjectTerms | Aged Amines - adverse effects Amines - therapeutic use Cyclohexanecarboxylic Acids - adverse effects Cyclohexanecarboxylic Acids - therapeutic use Double-Blind Method gamma-Aminobutyric Acid - adverse effects gamma-Aminobutyric Acid - therapeutic use Hot Flashes - drug therapy Hot Flashes - psychology Humans Longitudinal Studies Male Middle Aged Prostatic Neoplasms - complications Prostatic Neoplasms - mortality Prostatic Neoplasms - therapy Quality of Life Survivors |
Title | Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB |
URI | https://www.ncbi.nlm.nih.gov/pubmed/20552926 |
Volume | 8 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6lICEuFe_y1By4RUbrV2JzawO0QkrEwUi9VfuyQDS2RZJK7YFfwI9mZndtLxUg4OJEXieKdj5PPs98M8PYS5GqMibworF1RJQabymZR7pQJpZJLIykjO5yNTv5mL0_zU8nk--Bamm3la_U1S_rSv7HqngO7UpVsv9g2eFL8QS-R_viES2Mx7-y8bGQoiO5z6gWXA9yFksD2-20Rn78yTi5OJV4ILkkqZeiNs47dBQX7deNK3k-b2l40U7bQVmkYf_cuEbgVm14Ga0Wi-p4Wtk5HyvOF0chsx1rzCy73ew6YvakS2ob9VPsfomo23xx8dw1BTJG0eIh0VEv6P8g1uZcBGmrq0vt8kSuLH46RIeORP-ZN5QG94UUPpThsvA-lOG9b5ZFs7mbety75yJAYRq42tgVlQdm7tbWzgnP86R0dfh_Xr3Wabtf2mN784K85YoiP-5fHYmNHXY3_ETqIu2vv_ZEYplJdYft-02HQ4ePu2ximnvs1tKLJu6zbyNMAGECuMcwwgTaGhAm4GECeFEPE3AwgQEmr0FACBIIQQIBSMCCBCxIHrDq3dtqcRL5sRtRh2x3G8WC2hKqeM6lSAs10-TTZ0YJfLg2KefaZPgiMyl4nehCFhJpNDLVel7opE6Th-xG0zbmgIHkCvlrrmWZySytU6lFXhZc5NrIUqvkMXvkNu6sc61VzvotffLblafs9gidZ-xmjfeyeY7EcCtfWIv9AFmyaZU |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gabapentin+for+the+management+of+hot+flashes+in+prostate+cancer+survivors%3A+a+longitudinal+continuation+Study-NCCTG+Trial+N00CB&rft.jtitle=The+Journal+of+supportive+oncology&rft.au=Moraska%2C+Amanda+R&rft.au=Atherton%2C+Pamela+J&rft.au=Szydlo%2C+Daniel+W&rft.au=Barton%2C+Debra+L&rft.date=2010-05-01&rft.issn=1544-6794&rft.volume=8&rft.issue=3&rft.spage=128&rft_id=info%3Apmid%2F20552926&rft_id=info%3Apmid%2F20552926&rft.externalDocID=20552926 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1544-6794&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1544-6794&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1544-6794&client=summon |